Small Intestine Cancer - Video

Small intestine cancer is a rare form of cancer that occurs in the small intestine, a section of the digestive system between the stomach and large intestine. It accounts for less than 5% of all gastrointestinal cancers, with adenocarcinomas being the most common type, though other subtypes such as carcinoid tumors, lymphomas, and gastrointestinal stromal tumors (GISTs) can also develop. Typically diagnosed in people over 60 years of age, it is more common in men than women. Small intestine cancer can develop in any part of the small intestine, including the duodenum, jejunum, and ileum, but each type of cancer has a tendency to occur in specific areas.

The exact cause of small intestine cancer remains unclear, but several risk factors have been identified. Chronic conditions such as Crohn’s disease and celiac disease, which cause long-term inflammation of the intestine, increase the risk. Genetic disorders like familial adenomatous polyposis (FAP), Lynch syndrome, and Peutz-Jeghers syndrome are also associated with a higher risk. Other factors such as cigarette smoking, high-fat diets, and exposure to radiation can also contribute to the development of the disease. Additionally, a family history of small intestine cancer may increase the likelihood of developing this cancer.

Symptoms of small intestine cancer are often vague and can be mistaken for other gastrointestinal conditions, making it difficult to diagnose early. Common symptoms include abdominal pain, bloating, nausea, and vomiting. Weight loss, anemia, and intestinal obstruction are also frequent signs. Some patients may experience melena (black stools) or rectal bleeding if the tumor causes bleeding. In more advanced cases, jaundice can occur if the tumor blocks the bile duct. The asymptomatic nature of the disease in its early stages often leads to delayed diagnosis, resulting in more advanced disease at the time of detection.

To diagnose small intestine cancer, doctors typically use a combination of imaging studies, endoscopic procedures, and biopsies. Methods such as endoscopy and capsule endoscopy can directly visualize the tumor and collect tissue samples. CT scans, MRI, and PET-CT scans help assess the extent of the disease, including tumor size, location, and possible metastasis. A definitive diagnosis is confirmed through a biopsy that allows for the identification of the cancer type.

Small intestine cancer can manifest as different types of tumors, including adenocarcinomas, carcinoid tumors, lymphomas, and GISTs. Adenocarcinomas usually develop in the duodenum and are associated with chronic conditions like celiac disease. Carcinoid tumors, typically found in the ileum, may secrete hormones causing symptoms like flushing and diarrhea. Lymphomas, although rare, can occur in the small intestine, particularly in immunocompromised individuals. GISTs, which arise from cells in the wall of the small intestine, are generally benign but can sometimes be malignant.

Treatment for small intestine cancer generally involves surgery to remove the tumor. Chemotherapy is used for tumors that cannot be surgically removed, especially in cases of adenocarcinomas and lymphomas. Radiation therapy may also be used in some cases. Targeted therapy is employed for GISTs, with drugs like imatinib being used to block specific molecules that promote tumor growth. The prognosis varies depending on the type of cancer and the stage at diagnosis. Early-stage cancers that are surgically removed have a relatively good prognosis, with a 5-year survival rate of 60-80%. However, advanced-stage cancers or those that have spread to other organs have a poorer prognosis.

In conclusion, small intestine cancer, while rare, presents significant challenges due to its nonspecific symptoms and the difficulty of early detection. Treatment typically involves a combination of surgery, chemotherapy, and targeted therapies, with the prognosis improving with early diagnosis. Efforts to better understand the molecular mechanisms of this cancer may lead to more effective treatments in the future.